Retatrutide
Also known as: LY3437943, GLP-3 agonist, Triple-G agonist
A first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Demonstrated the highest weight loss percentages in Phase 2 clinical trials of any peptide to date.
Available from Nexis Labs
Retatrutide (GLP-3)
Sizes: 20mg
From $150.00
Overview
Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three incretin and metabolic hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple agonism is designed to maximize metabolic benefits by combining the appetite suppression and insulin secretion of GLP-1/GIP with the energy expenditure and lipolysis driven by glucagon signaling.
In Phase 2 clinical trials published in the New England Journal of Medicine (2023), participants receiving the highest dose of retatrutide achieved an average body weight reduction of approximately 24% at 48 weeks — exceeding results seen with any single or dual receptor agonist in comparable timeframes. The compound is currently advancing through Phase 3 development.
Mechanism of Action
Retatrutide is a long-chain fatty acid-modified peptide that activates GLP-1R, GIPR, and GcgR. GLP-1R activation reduces appetite and slows gastric emptying; GIPR activation enhances insulin secretion and may sensitize adipose tissue to GLP-1 effects; GcgR activation increases hepatic glucose output suppression, thermogenesis, and lipolysis. The combination creates additive or synergistic metabolic effects.
Research Areas
- ●Obesity and body weight reduction research
- ●Type 2 diabetes glycemic control
- ●Non-alcoholic fatty liver disease (NAFLD/MASH)
- ●Cardiovascular risk factor reduction
- ●Triple incretin receptor pharmacology
- ●Metabolic rate and energy expenditure studies
Storage & Handling
Store lyophilized at -20°C. Reconstituted solution: 2–8°C, use within 28 days. Avoid freeze-thaw cycles.
Soluble in sterile water; handle gently to preserve peptide integrity
For Research Use Only. This information is provided for educational and research purposes. Retatrutide is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.